Please login to the form below

Not currently logged in
Email:
Password:

Hanover Brussels appoints Aurélie Marchand as account director

She joins the communications consultancy from Hill & Knowlton Strategies Paris

Aurelie MarchlandHanover Brussels has bolstered its policy team with a new senior hire in the form of Aurélie Marchand, who joins the communications and public affairs consultancy as its EU health account director.

She joins the group from Hill & Knowlton Strategies Paris, where she spent the past six years as its public affairs lead advising healthcare and FMCG clients.

Marchand said: “I am extremely honoured to join such a renowned and forward-thinking agency.

“Coming from a country where market access and negotiations around pricing and reimbursement can be challenging, I’m eager to bring this experience to the EU level.”

Prior to Hill & Knowlton, Marchand served Sanofi, where she worked on French Parliament relations and she has held several positions within the French administration working for general secretariat for European affairs and the Ministry of Immigration.

Emma Eatwell, director of EU healthcare, Hanover, said: “With her [Marchand] wealth of experience at both national and European level, she will be an excellent addition to our team and will be instrumental in continuing the growth of our business.”

In her new role, Marchand will report to Eatwell and she will oversee the group’s portfolio of clients, which includes Sanofi Pasteur and Vertex Pharmaceuticals.

19th November 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics